A trial of prazosin for combat trauma PTSD with nightmares in active-duty soldiers returned from Iraq and Afghanistan

American Journal of Psychiatry

Volumn 170, Issue 9, 2013, Pages 1003-1010

  Raskind, Murray A ^a   Peterson, Kris ^a   Williams, Tammy ^a   Hoff, David J ^a   Hart, Kimberly ^a   Holmes, Hollie ^a   Homas, Dallas ^a   Hill, Jeffrey ^a   Daniels, Colin ^a   Calohan, Jess ^a   Millard, Steven P ^a   Rohde, Kirsten ^a   O'Connell, James ^a   Pritzl, Denise ^a   Feiszli, Kevin ^a   Petrie, Eric C ^a   Gross, Christopher ^a   Mayer, Cynthia L ^a   Freed, Michael C ^a   Engel, Charles ^a   Peskind, Elaine R ^a   more..

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PRAZOSIN;

ADULT; AFGHANISTAN; ARTICLE; BEDTIME DOSAGE; BLOOD PRESSURE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICIAN ADMINISTERED POSTTRAUMATIC STRESS DISORDER SCALE; CONTROLLED STUDY; DEPRESSION; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FAINTNESS; FEMALE; HAMILTON SCALE; HEART PALPITATION; HUMAN; IRAQ; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MUSCLE WEAKNESS; NIGHTMARE; NOSE OBSTRUCTION; OUTCOME ASSESSMENT; PITTSBURGH SLEEP QUALITY INDEX; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; PSYCHOTHERAPY; QUALITY OF LIFE INDEX; RANDOMIZED CONTROLLED TRIAL; SLEEP QUALITY; SOLDIER; TREATMENT DURATION; WAR;

EID: 84883689561     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2013.12081133     Document Type: Article

References (40)

1. Thomas JL, Wilk JE, Riviere LA, McGurk D, Castro CA, Hoge CW: Prevalence of mental health problems and functional impairment among active component and National Guard soldiers 3 and 12 months following combat in Iraq. Arch Gen Psychiatry 2010; 67:614-623
2. Morgan M, Lockwood A, Steinke D, Schleenbaker R, Botts S: Pharmacotherapy regimens among patients with posttraumatic stress disorder and mild traumatic brain injury. Psychiatr Serv 2012; 63:182-185
3. Department of Veterans Affairs, Department of Defense: VA/ DoD Clinical Practice Guideline: Management of Post-Traumatic Stress, version 2.0. Oct 2010 (http://www.healthquality.va.gov/ PTSD-FULL-2010c.pdf)
4. van der Kolk BA, Dreyfuss D, Michaels M, Shera D, Berkowitz R, Fisler R, Saxe G: Fluoxetine in posttraumatic stress disorder. J Clin Psychiatry 1994; 55:517-522
5. Hertzberg MA, Feldman ME, Beckham JC, Kudler HS, Davidson JRT: Lack of efficacy for fluoxetine in PTSD: a placebo controlled trial in combat veterans. Ann Clin Psychiatry 2000; 12: 101-105
6. Friedman MJ, Marmar CR, Baker DG, Sikes CR, Farfel GM: Randomized, double-blind comparison of sertraline and placebo for posttraumatic stress disorder in a Department of Veterans Affairs setting. J Clin Psychiatry 2007; 68:711-720
7. Southwick SM, Krystal JH, Morgan CA, Johnson D, Nagy LM, Nicolaou A, Heninger GR, Charney DS: Abnormal noradrenergic function in posttraumatic stress disorder. Arch Gen Psychiatry 1993; 50:266-274
8. Mellman TA, Kumar A, Kulick-Bell R, Kumar M, Nolan B: Nocturnal/daytime urine noradrenergic measures and sleep in combat-related PTSD. Biol Psychiatry 1995; 38:174-179
9. Geracioti TD Jr, Baker DG, Ekhator NN, West SA, Hill KK, Bruce AB, Schmidt D, Rounds-Kugler B, Yehuda R, Keck PE Jr, Kasckow JW: CSF norepinephrine concentrations in posttraumatic stress disorder. Am J Psychiatry 2001; 158:1227-1230
10. Blake DD, Weathers FW, Nagy LM, Kaloupek DG, Gusman FD, Charney DS, Keane TM: The development of a clinicianadministered PTSD scale. J Trauma Stress 1995; 8:75-90
11. Berridge CW: The locus ceruleus-noradrenergic system and stress: implications for post-traumatic stress disorder, in Post- Traumatic Stress Disorder: Basic Science and Clinical Practice. Edited by Shiromani PJ, Keane TM, LeDoux JE. New York, Humana Press, 2009, pp 213-230
12. Menkes DB, Baraban JM, Aghajanian GK: Prazosin selectively antagonizes neuronal responses mediated by alpha1-adrenoreceptors in brain. Naunyn Schmiedebergs Arch Pharmacol 1981; 317: 273-275
13. Raskind MA, Peskind ER, Kanter ED, Petrie EC, Radant A, Thompson CE, Dobie DJ, Hoff D, Rein RJ, Straits-Tröster K, Thomas RG, McFall MM: Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebocontrolled study. Am J Psychiatry 2003; 160:371-373
14. Raskind MA, Peskind ER, Hoff DJ, Hart KL, Holmes HA, Warren D, Shofer J, O'Connell J, Taylor F, Gross C, Rohde K, McFall ME: A parallel group placebo controlled study of prazosin for trauma nightmares and sleep disturbance in combat veterans with post-traumatic stress disorder. Biol Psychiatry 2007; 61:928-934
15. Germain A, Richardson R, Moul DE, Mammen O, Haas G, Forman SD, Rode N, Begley A, Nofzinger EA: Placebo-controlled comparison of prazosin and cognitive-behavioral treatments for sleep disturbances in USmilitary veterans. J Psychosom Res 2012; 72:89-96
16. First MB, Spitzer RL, Gibbon M, William JBW: Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition (SCID-IP, Version 2.0). New York, Biometrics Research Department, New York State Psychiatric Institute, 1996
17. Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ: The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989; 28:193-213
18. Guy W: ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Washington, DC, US Department of Health, Education, and Welfare, 1976, pp 218-222
19. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56-62
20. Kroenke K, Spitzer RL, Williams JB: The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001; 16: 606-613
21. Frisch MB: Manual and Treatment Guide for the Quality of Life Inventory-QOLI. Minneapolis, MN, Pearson Assessments, 1994
22. Pinheiro JC, Bates DM: Mixed-Effects Models in S and S-PLUS. New York, Springer, 2000
23. R Development Core Team: R: A Language and Environment for Statistical Computing, version 2.11.1. Vienna, Austria, R Foundation for Statistical Computing, 2011 (http://www.R-project.org)
24. Pinheiro J, Bates D, DebRoy S, Sarkar D, R Core Team: nlme: Linear and Nonlinear Mixed Effects Models, R package, version 3.1-104, 2012. http://cran.r-project.org/web/packages/nlme
25. Bates D, Maechler M, Bolker B: lme4: Linear mixed-effects models using S4 classes, R package, version 0.999999-0, 2012. http://CRAN.R-project.org/ package=lme4
26. Westfall TC, Westfall DP: Adrenergic agonists and antagonists, in Goodman and Gilman's The Pharmacological Basis of Therapeutics, 11th ed. Edited by Brunton L, Lazo T, Barker K. New York, McGraw-Hill, 2006, pp 237-296
27. Krystal JH, Rosenheck RA, Cramer JA, Vessicchio JC, Jones KM, Vertrees JE, Horney RA, Huang GD, Stock C; Veterans Affairs Cooperative Study No. 504 Group: Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD: a randomized trial. JAMA 2011; 306:493-502
28. Brady K, Pearlstein T, Asnis GM, Baker D, Rothbaum B, Sikes CR, Farfel GM: Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial. JAMA 2000; 283:1837-1844
29. Davidson JRT, Rothbaum BO, van der Kolk BA, Sikes CR, Farfel GM: Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Arch Gen Psychiatry 2001; 58:485-492
30. Tucker P, Zaninelli R, Yehuda R, Ruggiero L, Dillingham K, Pitts CD: Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry 2001; 62:860-868
31. Marshall RD, Beebe KL, Oldham M, Zaninelli R: Efficacy and safety of paroxetine treatment for chronic PTSD: a fixeddose, placebo-controlled study. Am J Psychiatry 2001; 158: 1982-1988
32. Oberndorfer S, Saletu-Zyhlarz G, Saletu B: Effects of selective serotonin reuptake inhibitors on objective and subjective sleep quality. Neuropsychobiology 2000; 42:69-81
33. Taylor FB, Martin P, Thompson C, Williams J, Mellman TA, Gross C, Peskind ER, Raskind MA: Prazosin effects on objective sleep measures and clinical symptoms in civilian trauma postraumatic stress disorder: a placebo-controlled study. Biol Psychiatry 2008; 63:629-632
34. Ruff RL, Ruff SS, Wang XF: Improving sleep: initial headache treatment in OIF/OEF veterans with blast-induced mild traumatic brain injury. J Rehabil Res Dev 2009; 46:1071-1084
35. Calohan J, Peterson K, Peskind ER, Raskind MA: Prazosin treatment of trauma nightmares and sleep disturbance in soldiers deployed in Iraq. J Trauma Stress 2010; 23:645-648
36. Mallick BN, Majumdar S, Faisal M, Yadav V, Madan V, Pal D: Role of norepinephrine in the regulation of rapid eye movement sleep. J Biosci 2002; 27:539-551
37. Vythilingam M, Anderson GM, Owens MJ, Halaszynski TM, Bremner JD, Carpenter LL, Heninger GR, Nemeroff CB, Charney DS: Cerebrospinal fluid corticotropin-releasing hormone in healthy humans: effects of yohimbine and naloxone. J Clin Endocrinol Metab 2000; 85:4138-4145
38. Birnbaum S, Gobeske KT, Auerbach J, Taylor JR, Arnsten AF: A role for norepinephrine in stress-induced cognitive deficits: alpha-1-adrenoceptor mediation in the prefrontal cortex. Biol Psychiatry 1999; 46:1266-1274
39. Thompson CE, Taylor FB, McFall ME, Barnes RF, Raskind MA: Nonnightmare distressed awakenings in veterans with posttraumatic stress disorder: response to prazosin. J Trauma Stress 2008; 21:417-420
40. Eftekhari A, Ruzek JI, Crowley JJ, Rosen CS; National Center for PTSD: Effectiveness of national implementation of prolonged exposure therapy in VA care. JAMA Psychiatry (in press)